CIRM’s Alpha Clinics network specializes in delivering stem and gene therapy trials. Its success relies on strong partnerships with patients, clinicians, and trial sponsors. The network includes nine leading medical centers across California.

Each year, CIRM hosts a public Alpha Clinic Symposium to explore key issues in stem and gene therapies. UC Irvine hosted the sixth annual event.

The two‑day meeting brought together all nine Alpha Clinics to highlight efforts to improve access to treatment for California’s diverse communities.

Emily Crotti said the Alpha Clinics provide essential operational support for stem and gene therapy trials and aim to become centers of excellence for approved treatments.

Topics ranged from cell therapy for high blood pressure to curative treatments for hemoglobin disorders.

Keynote speaker Jonathan Watanabe discussed barriers to patient access. He stressed that access to affordable medicines is essential for public health and equity. He recommended faster use of generics, stronger government purchasing power, and Medicaid subscription‑based payment models.

Patient voices took center stage as well. Travis Winsor, a trial participant, said his diagnosis once felt like a death sentence. He thanked the community for expanding resources and support. Kim Cade emphasized the importance of research for rare diseases and shared her family’s experience with ALSP. She said advancing research offers vital hope for affected communities.

To learn more about the CIRM Alpha Clinics, visit our website.